2014

FDA Removes Partial Hold on TELCYTA Clinical Development

    PALO ALTO, Calif., Oct. 15 /PRNewswire-FirstCall/ -- Telik, Inc.
 (Nasdaq:   TELK) announced that the U.S. Food and Drug Administration (FDA)
 has removed the partial hold on TELCYTA(R) (canfosfamide HCl, TLK286)
 clinical trials. This action follows a complete review of TELCYTA data by
 the agency and permits the resumption of TELCYTA clinical development.
     Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on
 discovering, developing and commercializing novel small molecule drugs to
 treat serious diseases. The company's most advanced drug development
 candidates are TELCYTA, a tumor-activated small molecule product candidate
 in clinical development for the treatment of advanced ovarian cancer and
 non- small cell lung cancer; and TELINTRA(R), which is in clinical
 development for the treatment of myelodysplastic syndrome. Telik's product
 candidates were discovered using its proprietary drug discovery technology,
 TRAP(R), which enables the rapid and efficient discovery of small molecule
 drug candidates.
     This press release contains "forward-looking" statements, including
 statements regarding plans for future clinical development of TELCYTA.
 Words such as "will," "plans" and similar expressions are intended to
 identify forward-looking statements. These forward-looking statements are
 based upon Telik's current expectations. There are important factors that
 could cause Telik's results to differ materially from those indicated by
 these forward- looking statements, including, among others, that if
 clinical trials of TELCYTA are further delayed or unsuccessful, Telik's
 business would suffer, and if Telik does not obtain regulatory approval to
 market products in the United States and foreign countries, Telik will not
 be permitted to commercialize its product candidates. Detailed information
 regarding factors that may cause actual results to differ materially from
 the results expressed or implied by statements in this press release may be
 found in Telik's periodic filings with the Securities and Exchange
 Commission, including the factors described in the section entitled "Risk
 Factors" in its quarterly report on Form 10-Q for the quarter ended June
 30, 2007. Telik does not undertake any obligation to update forward-looking
 statements contained in this press release.
     TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or
 registered trademarks of Telik, Inc.
 
 

SOURCE Telik, Inc.

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.